Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 04/16/2024 at 14:30, 2 years ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology

Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product
BRIEF

published on 04/09/2024 at 22:20, 2 years 1 month ago

Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial

Jaguar Health Nasdaq Compliance Cancer Therapy Stockholder Meeting Crofelemer Clinical Trial
BRIEF

published on 04/09/2024 at 22:20, 2 years 1 month ago

Jaguar Health annonce une assemblée d’actionnaires réussie et des progrès dans les essais cliniques

Assemblée Générale Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai Clinique Crofelemer
PRESS RELEASE

published on 04/09/2024 at 22:15, 2 years 1 month ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting

Crofelemer Stockholders Meeting Jaguar Health Reverse Split Phase 3 Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 1 month ago

Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon

Crofelemer Jaguar Health Nasdaq Compliance Cancer Therapy OnTarget Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 1 month ago

Jaguar Health obtient une prolongation pour rétablir la conformité au Nasdaq et annonce bientôt les résultats de l'essai OnTarget

Crofelemer Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai OnTarget
PRESS RELEASE

published on 04/08/2024 at 14:30, 2 years 1 month ago

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial

Crofelemer Nasdaq Jaguar Health Cancer Therapy Grace Period
BRIEF

published on 04/02/2024 at 14:35, 2 years 1 month ago

Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International

Pharmaceutical Industry Crofelemer Jaguar Health Massimo Radaelli Commercial Expansion
BRIEF

published on 04/02/2024 at 14:35, 2 years 1 month ago

Jaguar Health, Inc. annonce la nomination d'un vétéran de l'industrie pharmaceutique européenne au poste de président de Jaguar International

Crofelemer Expansion Commerciale Industrie Pharmaceutique Santé Jaguar Massimo Radaelli
PRESS RELEASE

published on 04/02/2024 at 14:30, 2 years 1 month ago

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise

Pharmaceutical Industry Jaguar Health International Expansion Massimo Radaelli Out-license Agreement

Accesswire

Published on 05/09/2026 at 01:55, 1 day 18 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 18 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 18 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 20 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 21 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 4 hours 12 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 6 hours 17 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 8 hours 32 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 1 hour ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 23 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 1 hour ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 1 hour ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 1 hour ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 1 hour ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 1 hour ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE